CN105339357A - 适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物 - Google Patents
适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物 Download PDFInfo
- Publication number
- CN105339357A CN105339357A CN201480026453.XA CN201480026453A CN105339357A CN 105339357 A CN105339357 A CN 105339357A CN 201480026453 A CN201480026453 A CN 201480026453A CN 105339357 A CN105339357 A CN 105339357A
- Authority
- CN
- China
- Prior art keywords
- ethyl
- trans
- base
- pyrimidine
- cis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361786869P | 2013-03-15 | 2013-03-15 | |
| US61/786869 | 2013-03-15 | ||
| US201361918524P | 2013-12-19 | 2013-12-19 | |
| US61/918524 | 2013-12-19 | ||
| PCT/EP2014/055062 WO2014140246A1 (en) | 2013-03-15 | 2014-03-14 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105339357A true CN105339357A (zh) | 2016-02-17 |
Family
ID=50280387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480026453.XA Pending CN105339357A (zh) | 2013-03-15 | 2014-03-14 | 适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9388148B2 (https=) |
| EP (1) | EP2970146B1 (https=) |
| JP (1) | JP2016514117A (https=) |
| CN (1) | CN105339357A (https=) |
| AU (1) | AU2014230215A1 (https=) |
| BR (1) | BR112015021471A2 (https=) |
| CA (1) | CA2902656A1 (https=) |
| MX (1) | MX2015012184A (https=) |
| TW (1) | TW201514154A (https=) |
| UY (1) | UY35420A (https=) |
| WO (1) | WO2014140246A1 (https=) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020156312A1 (zh) * | 2019-01-30 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
| CN112239433A (zh) * | 2019-07-17 | 2021-01-19 | 北京盈科瑞创新药物研究有限公司 | 一种环己烷衍生物、制备方法及其应用 |
| WO2021083246A1 (zh) * | 2019-10-29 | 2021-05-06 | 上海翰森生物医药科技有限公司 | 四元环类衍生物调节剂、其制备方法和应用 |
| CN113754580A (zh) * | 2020-06-05 | 2021-12-07 | 上海中泽医药科技有限公司 | 一种吡啶吗啉类化合物、其制备方法及其应用 |
| WO2022228447A1 (zh) * | 2021-04-28 | 2022-11-03 | 上海翰森生物医药科技有限公司 | 含哌嗪多环类衍生物的盐及晶型及其制备方法和应用 |
| RU2833027C1 (ru) * | 2019-10-29 | 2025-01-13 | Шанхай Хэнсох Биомедикал Ко., Лтд. | Модификатор производного четырехчленного кольца, способ его получения и его применение |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| AR095264A1 (es) * | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| EP3495363B1 (en) | 2016-07-28 | 2023-08-23 | Shionogi & Co., Ltd | Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect |
| EP3744721B1 (en) | 2018-01-26 | 2025-07-02 | Shionogi & Co., Ltd. | Condensed ring compounds having dopamine d3 receptor antagonistic effect |
| JP7250405B2 (ja) | 2018-01-26 | 2023-04-03 | 塩野義製薬株式会社 | ドーパミンd3受容体拮抗作用を有する環式化合物 |
| TWI873212B (zh) * | 2019-10-29 | 2025-02-21 | 大陸商上海翰森生物醫藥科技有限公司 | 四員環類衍生物調節劑、其製備方法和應用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006066885A1 (de) * | 2004-12-21 | 2006-06-29 | Abbott Gmbh & Co. Kg | Substituierte n-heterocyclische verbindungen und ihre verwendung als dopamin d3 rezeptorliganden |
| US20090143398A1 (en) * | 2007-12-03 | 2009-06-04 | Gizella Bartane Szalai | Pyrimidinyl-piperazines useful as d3/d2 receptor ligands |
| CN101511805A (zh) * | 2006-06-22 | 2009-08-19 | 生物计划公司 | 作为多巴胺d3受体配体的新型羰基化(氮杂)环己烷类化合物 |
| CN102947310A (zh) * | 2010-06-21 | 2013-02-27 | 霍夫曼-拉罗奇有限公司 | 作为5-ht2a和d3受体的双重调节剂的稠合吡啶化合物 |
| CN102958936A (zh) * | 2010-07-06 | 2013-03-06 | 霍夫曼-拉罗奇有限公司 | 稠合的吡啶化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10311065A1 (de) | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung |
| TW200510395A (en) | 2003-06-05 | 2005-03-16 | Abbott Gmbh & Co Kg | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| DE102004027359A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
| DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
| ES2340941T3 (es) | 2004-08-09 | 2010-06-11 | ABBOTT GMBH & CO. KG | Compuestos de 4-piperazinil-pirimidina adecuados para tretar trastornos que responden a modulacion del receptor d 3 de dopamina. |
| HUP0500170A3 (en) | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
| WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| WO2009003868A2 (en) | 2007-07-02 | 2009-01-08 | F. Hoffmann-La Roche Ag | 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) |
| PA8802101A1 (es) | 2007-11-02 | 2009-08-26 | Abbott Gmbh & Co Kg | Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3 |
| JP5367824B2 (ja) * | 2008-09-22 | 2013-12-11 | エフ.ホフマン−ラ ロシュ アーゲー | ピペラジンd3及び5−ht2a受容体調節薬 |
| AU2009296047A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyridinylpiperazin derivatives useful as modulators of dopamine D3 receptors |
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
-
2014
- 2014-03-13 UY UY0001035420A patent/UY35420A/es not_active Application Discontinuation
- 2014-03-14 WO PCT/EP2014/055062 patent/WO2014140246A1/en not_active Ceased
- 2014-03-14 TW TW103109325A patent/TW201514154A/zh unknown
- 2014-03-14 JP JP2015562180A patent/JP2016514117A/ja active Pending
- 2014-03-14 MX MX2015012184A patent/MX2015012184A/es unknown
- 2014-03-14 BR BR112015021471A patent/BR112015021471A2/pt not_active IP Right Cessation
- 2014-03-14 US US14/213,169 patent/US9388148B2/en active Active
- 2014-03-14 CA CA2902656A patent/CA2902656A1/en not_active Abandoned
- 2014-03-14 CN CN201480026453.XA patent/CN105339357A/zh active Pending
- 2014-03-14 AU AU2014230215A patent/AU2014230215A1/en not_active Abandoned
- 2014-03-14 EP EP14710261.0A patent/EP2970146B1/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006066885A1 (de) * | 2004-12-21 | 2006-06-29 | Abbott Gmbh & Co. Kg | Substituierte n-heterocyclische verbindungen und ihre verwendung als dopamin d3 rezeptorliganden |
| CN101511805A (zh) * | 2006-06-22 | 2009-08-19 | 生物计划公司 | 作为多巴胺d3受体配体的新型羰基化(氮杂)环己烷类化合物 |
| US20090143398A1 (en) * | 2007-12-03 | 2009-06-04 | Gizella Bartane Szalai | Pyrimidinyl-piperazines useful as d3/d2 receptor ligands |
| CN102947310A (zh) * | 2010-06-21 | 2013-02-27 | 霍夫曼-拉罗奇有限公司 | 作为5-ht2a和d3受体的双重调节剂的稠合吡啶化合物 |
| CN102958936A (zh) * | 2010-07-06 | 2013-03-06 | 霍夫曼-拉罗奇有限公司 | 稠合的吡啶化合物 |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111770754A (zh) * | 2019-01-30 | 2020-10-13 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
| WO2020156312A1 (zh) * | 2019-01-30 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
| CN111770754B (zh) * | 2019-01-30 | 2023-09-19 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
| TWI850321B (zh) * | 2019-01-30 | 2024-08-01 | 大陸商江蘇豪森藥業集團有限公司 | 一種多環類衍生物調節劑、其製備方法和應用 |
| CN112239433A (zh) * | 2019-07-17 | 2021-01-19 | 北京盈科瑞创新药物研究有限公司 | 一种环己烷衍生物、制备方法及其应用 |
| CN112239433B (zh) * | 2019-07-17 | 2024-05-14 | 北京盈科瑞创新药物研究有限公司 | 一种环己烷衍生物、制备方法及其应用 |
| RU2833027C1 (ru) * | 2019-10-29 | 2025-01-13 | Шанхай Хэнсох Биомедикал Ко., Лтд. | Модификатор производного четырехчленного кольца, способ его получения и его применение |
| WO2021083246A1 (zh) * | 2019-10-29 | 2021-05-06 | 上海翰森生物医药科技有限公司 | 四元环类衍生物调节剂、其制备方法和应用 |
| CN113056454A (zh) * | 2019-10-29 | 2021-06-29 | 上海翰森生物医药科技有限公司 | 四元环类衍生物调节剂、其制备方法和应用 |
| CN113754580A (zh) * | 2020-06-05 | 2021-12-07 | 上海中泽医药科技有限公司 | 一种吡啶吗啉类化合物、其制备方法及其应用 |
| CN113754580B (zh) * | 2020-06-05 | 2023-04-25 | 上海中泽医药科技有限公司 | 一种吡啶吗啉类化合物、其制备方法及其应用 |
| US12410136B2 (en) | 2020-06-05 | 2025-09-09 | Shanghai Zhongze Therapeutics, Co. Ltd. | Pyridinyl morpholine compound, preparation method therefor, and application thereof |
| WO2022228447A1 (zh) * | 2021-04-28 | 2022-11-03 | 上海翰森生物医药科技有限公司 | 含哌嗪多环类衍生物的盐及晶型及其制备方法和应用 |
| CN117242058A (zh) * | 2021-04-28 | 2023-12-15 | 上海翰森生物医药科技有限公司 | 含哌嗪多环类衍生物的盐及晶型及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016514117A (ja) | 2016-05-19 |
| EP2970146A1 (en) | 2016-01-20 |
| AU2014230215A1 (en) | 2015-09-03 |
| TW201514154A (zh) | 2015-04-16 |
| WO2014140246A1 (en) | 2014-09-18 |
| CA2902656A1 (en) | 2014-09-18 |
| US20140303176A1 (en) | 2014-10-09 |
| EP2970146B1 (en) | 2017-11-01 |
| BR112015021471A2 (pt) | 2017-07-18 |
| UY35420A (es) | 2014-10-31 |
| MX2015012184A (es) | 2016-05-16 |
| US9388148B2 (en) | 2016-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105339357A (zh) | 适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物 | |
| CN104854103B (zh) | 适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物 | |
| WO2021127459A1 (en) | Gpr139 receptor modulators | |
| RU2478633C2 (ru) | Производные 1,2,4-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3 | |
| US9388141B2 (en) | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | |
| CN101918384A (zh) | 适合治疗响应5-羟色胺5-ht6受体调节的疾病的苯磺酰苯胺化合物 | |
| EP2203426B1 (en) | Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor | |
| CN116323583A (zh) | 用于对亨廷顿蛋白成像的杂联芳基化合物和显像剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160217 |
|
| RJ01 | Rejection of invention patent application after publication |